Drug Profile
DS 8895
Alternative Names: DS-8895aLatest Information Update: 22 Mar 2019
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Developer Daiichi Sankyo Company; Ludwig Institute for Cancer Research
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action EphA2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 22 Mar 2019 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV) (Daiichi Sankyo website, March 2019)
- 28 Mar 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater, Metastatic disease) in Australia (IV, Infusion)
- 01 May 2017 Discontinued - Phase-I for Solid tumours (Late-stage disease) in Japan (IV) (Daiichi Sankyo pipeline, May 2017)